A phase 2B long-term, randomized, open-label, safety and tolerability trial comparing [S,S]-reboxetine (PNU-165442G) with routine care in patients with postherpetic neuralgia (PHN)
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2007
At a glance
- Drugs Esreboxetine (Primary)
- Indications Postherpetic neuralgia
- Focus Adverse reactions
- Sponsors Pfizer
- 07 Nov 2007 Status changed from in progress to discontinued. The study was stopped due to business/operational issues.
- 10 Oct 2007 Status changed from recruiting to in progress.
- 27 Jan 2007 New trial centre added